| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | J S Malter | |
| B C Ray | |||
| C J Westmark | |||
| P R Westmark | |||
| P2860 | cites work | Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice | Q22242267 |
| Homer Binds TRPC Family Channels and Is Required for Gating of TRPC1 by IP3 Receptors | Q24295021 | ||
| Altered synaptic plasticity in a mouse model of fragile X mental retardation | Q24530695 | ||
| Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function | Q24608468 | ||
| Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior | Q24645994 | ||
| A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. | Q24654933 | ||
| Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism | Q24674309 | ||
| Evidence that fragile X mental retardation protein is a negative regulator of translation | Q28117211 | ||
| The fragile X mental retardation protein binds and regulates a novel class of mRNAs containing U rich target sequences | Q28117418 | ||
| CLIP identifies Nova-regulated RNA networks in the brain | Q28184312 | ||
| The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses | Q28208647 | ||
| Neuronal and glial mGluR5 modulation prevents stretch-induced enhancement of NMDA receptor current | Q28214617 | ||
| The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning | Q28244264 | ||
| From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome | Q28247567 | ||
| Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity | Q28263355 | ||
| Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome | Q28273791 | ||
| Phenyl ureas of creatinine as mGluR5 antagonists. A structure-activity relationship study of fenobam analogues | Q28288954 | ||
| The fragile X mental retardation protein binds specifically to its mRNA via a purine quartet motif | Q28348391 | ||
| Metabotropic glutamate receptor subtypes 1 and 5 are activators of extracellular signal-regulated kinase signaling required for inflammatory pain in mice | Q28571306 | ||
| Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus | Q28592777 | ||
| Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway | Q28854318 | ||
| Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1 alpha, mGluR2 and mGluR5, relative to neurotransmitter release sites | Q29144166 | ||
| Dendritic spine changes associated with hippocampal long-term synaptic plasticity | Q29614373 | ||
| The mGluR theory of fragile X mental retardation | Q29615060 | ||
| Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function | Q29616372 | ||
| Pharmacology and functions of metabotropic glutamate receptors | Q29619150 | ||
| Seizure susceptibility and mortality in mice that over-express amyloid precursor protein | Q30482779 | ||
| Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice | Q30488610 | ||
| FMRP mediates mGluR5-dependent translation of amyloid precursor protein | Q33273636 | ||
| Roles of metabotropic glutamate receptors in LTP and LTD in the hippocampus | Q33680954 | ||
| The fragile X mental retardation protein is required for type-I metabotropic glutamate receptor-dependent translation of PSD-95 | Q33717210 | ||
| Ligands for glutamate receptors: design and therapeutic prospects | Q33967605 | ||
| Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors | Q34029499 | ||
| Neutrophil-derived glutamate regulates vascular endothelial barrier function | Q34114299 | ||
| Synaptic regulation of protein synthesis and the fragile X protein | Q34287475 | ||
| Novel allosteric antagonists shed light on mglu(5) receptors and CNS disorders | Q34296075 | ||
| Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation | Q34325464 | ||
| Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors | Q34410375 | ||
| Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses | Q37184743 | ||
| Altered hippocampal synaptic plasticity in the FMR1 gene family knockout mouse models | Q37190453 | ||
| Thin, stubby or mushroom: spine pathology in Alzheimer's disease | Q37515498 | ||
| Gene expression profiles in a transgenic animal model of fragile X syndrome | Q38362679 | ||
| Distribution and activity of alternatively spliced alzheimer amyloid peptide precursor and scrapie PrP mRNAs on rat brain polysomes | Q41135121 | ||
| Phosphorylation of FMRP inhibits association with Dicer | Q43161216 | ||
| Fragile X mental retardation protein is required for chemically-induced long-term potentiation of the hippocampus in adult mice. | Q43297720 | ||
| Selective mGluR5 receptor antagonist or agonist provides neuroprotection in a rat model of focal cerebral ischemia | Q43823127 | ||
| MGLuR5 activation reduces beta-amyloid-induced cell death in primary neuronal cultures and attenuates translocation of cytochrome c and apoptosis-inducing factor | Q44930741 | ||
| Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome | Q44959699 | ||
| Group I metabotropic glutamate receptors, mGlu1a and mGlu5a, couple to cyclic AMP response element binding protein (CREB) through a common Ca2+ - and protein kinase C-dependent pathway | Q46386590 | ||
| Selectively enriched mRNAs in rat synaptoneurosomes | Q47317299 | ||
| Up-regulation of astrocyte metabotropic glutamate receptor 5 by amyloid-β peptide | Q47922566 | ||
| Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia | Q48251087 | ||
| The up-regulation of metabotropic glutamate receptor 5 (mGluR5) in Down's syndrome brains | Q48255681 | ||
| Metabotropic glutamate receptors prevent programmed cell death through the modulation of neuronal endonuclease activity and intracellular pH. | Q48299574 | ||
| Adult fragile X syndrome. Clinico-neuropathologic findings | Q48545759 | ||
| The Fra(X) syndrome: neurological, electrophysiological, and neuropathological abnormalities | Q48801261 | ||
| Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. | Q53219086 | ||
| Selective blockade of mGlu5 metabotropic glutamate receptors protects rat hepatocytes against hypoxic damage | Q73520234 | ||
| P433 | issue | 3 | |
| P921 | main subject | fragile X syndrome | Q221472 |
| Alzheimer's disease | Q11081 | ||
| P304 | page(s) | 200-206 | |
| P577 | publication date | 2010-05-01 | |
| P1433 | published in | Current Alzheimer Research | Q5195031 |
| P1476 | title | Fragile X Syndrome and Alzheimer's Disease: Another story about APP and beta-amyloid | |
| P478 | volume | 7 |
| Q52130370 | Analysis of peripheral amyloid precursor protein in Angelman Syndrome. |
| Q90098726 | Attenuation of Acute Intracerebral Hemorrhage-Induced Microglial Activation and Neuronal Death Mediated by the Blockade of Metabotropic Glutamate Receptor 5 In Vivo |
| Q34607724 | Cellular stress-induced up-regulation of FMRP promotes cell survival by modulating PI3K-Akt phosphorylation cascades |
| Q41073215 | Developing BACE-1 inhibitors for FXS. |
| Q53321175 | Editorial: can we improve care for patients with dementia? |
| Q57156403 | Fragile X and APP: a Decade in Review, a Vision for the Future |
| Q35077291 | Fragile X mental retardation protein: from autism to neurodegenerative disease. |
| Q30410502 | From FMRP function to potential therapies for fragile X syndrome |
| Q35492486 | Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome |
| Q30580280 | Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease |
| Q28279479 | PAK in Alzheimer disease, Huntington disease and X-linked mental retardation |
| Q43186010 | Protein kinase A directly phosphorylates metabotropic glutamate receptor 5 to modulate its function |
| Q27023257 | Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes |
| Q27010675 | The pathophysiology of fragile X (and what it teaches us about synapses) |
| Q36110142 | The regulation of AβPP expression by RNA-binding proteins |
| Q28069294 | The struggle by Caenorhabditis elegans to maintain proteostasis during aging and disease |
| Q36424785 | Translational Concepts of mGluR5 in Synaptic Diseases of the Brain |
| Q38038399 | What's hAPPening at synapses? The role of amyloid β-protein precursor and β-amyloid in neurological disorders |
| Q37712328 | c-Jun N-terminal kinase regulates mGluR-dependent expression of post-synaptic FMRP target proteins. |
Search more.